CN115484966A - 治疗和预防植入性心律失常的方法 - Google Patents

治疗和预防植入性心律失常的方法 Download PDF

Info

Publication number
CN115484966A
CN115484966A CN202180027573.1A CN202180027573A CN115484966A CN 115484966 A CN115484966 A CN 115484966A CN 202180027573 A CN202180027573 A CN 202180027573A CN 115484966 A CN115484966 A CN 115484966A
Authority
CN
China
Prior art keywords
amiodarone
administration
ivabradine
cardiomyocytes
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027573.1A
Other languages
English (en)
Chinese (zh)
Inventor
比约恩·科诺尔曼
罗伯特·斯科特·蒂斯
威廉·罗伯特·梅克莱兰
肯塔·纳卡穆拉
查尔斯·E·莫里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Vanderbilt University
Original Assignee
University of Washington
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Vanderbilt University filed Critical University of Washington
Publication of CN115484966A publication Critical patent/CN115484966A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180027573.1A 2020-02-10 2021-02-09 治疗和预防植入性心律失常的方法 Pending CN115484966A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
US62/972,330 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (1)

Publication Number Publication Date
CN115484966A true CN115484966A (zh) 2022-12-16

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027573.1A Pending CN115484966A (zh) 2020-02-10 2021-02-09 治疗和预防植入性心律失常的方法

Country Status (11)

Country Link
US (1) US20230077983A1 (https=)
EP (1) EP4103206A4 (https=)
JP (1) JP2023512843A (https=)
KR (1) KR20220140532A (https=)
CN (1) CN115484966A (https=)
AU (1) AU2021218653A1 (https=)
BR (1) BR112022015768A2 (https=)
CA (1) CA3166678A1 (https=)
IL (1) IL295236A (https=)
MX (1) MX2022009807A (https=)
WO (1) WO2021163037A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
WO2023173123A1 (en) * 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
EP4593821A2 (en) * 2022-09-28 2025-08-06 Bluerock Therapeutics LP Compositions and methods for treating graft-related arrhythmia
WO2025137525A1 (en) * 2023-12-22 2025-06-26 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151755A1 (en) * 2012-04-04 2013-10-10 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
US20140363841A1 (en) * 2012-01-20 2014-12-11 Singapore Health Services Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof
WO2016176333A1 (en) * 2015-04-27 2016-11-03 Reflex Medical, Inc. Systems and mehtods for sympathetic cardiopulmonary neuromodulation
WO2018170280A1 (en) * 2017-03-15 2018-09-20 University Of Washington Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140363841A1 (en) * 2012-01-20 2014-12-11 Singapore Health Services Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof
WO2013151755A1 (en) * 2012-04-04 2013-10-10 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
WO2016176333A1 (en) * 2015-04-27 2016-11-03 Reflex Medical, Inc. Systems and mehtods for sympathetic cardiopulmonary neuromodulation
WO2018170280A1 (en) * 2017-03-15 2018-09-20 University Of Washington Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANA-KATHARINA DIEKS等: "Adjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia", HEART RHYTHM., vol. 13, no. 6, 30 June 2016 (2016-06-30), pages 2 - 3 *
KAZUNORI UEMURA等: "Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs", HEART VESSELS, 14 November 2016 (2016-11-14), pages 1 *
YEN-WEN LIU等: "Human ESC-Derived Cardiomyocytes Restore Function in Infarcted Hearts of Non-Human Primates", NAT BIOTECHNOL., vol. 37, no. 7, 31 August 2018 (2018-08-31), pages 4 *

Also Published As

Publication number Publication date
IL295236A (en) 2022-10-01
JP2023512843A (ja) 2023-03-29
MX2022009807A (es) 2022-11-10
AU2021218653A1 (en) 2022-09-01
EP4103206A4 (en) 2024-03-13
US20230077983A1 (en) 2023-03-16
KR20220140532A (ko) 2022-10-18
BR112022015768A2 (pt) 2022-11-22
WO2021163037A1 (en) 2021-08-19
EP4103206A1 (en) 2022-12-21
CA3166678A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CN115484966A (zh) 治疗和预防植入性心律失常的方法
Biressi et al. Stem cell therapy for muscular dystrophies
López et al. Wharton's jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report
US11969459B2 (en) Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
CN103221058B (zh) 用于心脏修复的骨髓衍生cd271前体细胞
JP7091427B2 (ja) 心不全の治療方法
JP2012518041A (ja) 心不整脈を予防するための組成物および方法
Dariolli et al. Allogeneic pASC transplantation in humanized pigs attenuates cardiac remodeling post-myocardial infarction
US20160015860A1 (en) Micro-tissue particles and methods for their use in cell therapy
US8889122B2 (en) Cellular cardiomyoplasty as supportive therapy in patients with heart disease
US20230250393A1 (en) Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
Johnston et al. Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study
Rheault-Henry et al. Therapeutic Uses of Stem Cells for Heart Failure: Hype or Hope
Akar et al. Failing heart; remodel, replace or repair?/Terminal dönem kalp yetersizligi: Kalp nakli mi? Yeniden biçimlendirme mi? Yoksa onarim mi?
Gómez Cid Development, characterization and evaluation of advanced therapies for the treatment of cardiac pathologies
Rheault-Henry et al. Unraveling the Mystery of Regenerative Medicine in the Treatment of Heart Failure
CN121586768A (zh) 心肌细胞群、药物组合物、制备心肌细胞群的方法和心肌细胞球体
WO2015006510A1 (en) Methods for treating an established myocardial infarction
Nakamura et al. Article Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes
Rodrigo Intramyocardial bone marrow cell injection for ischemic heart disease: efficacy
Noiseux et al. STEM CELLS THERAPY FOR ISCHEMIC CARDIOVASCULAR DISEASES: NEW INSIGHTS ON MECHANISMS AND FATE OF THE IMPLANTED CELLS
Al-Nbaheen Mesenchymal Stromal Cells in Cardiovascular Disease
Noiseux et al. Autologous Stem Cells for Cardiac Repair: New Insights on Clinical Trial Safety and Best Cell Source
Tchao Engineered human cardiac tissue from muscle derived stem cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination